Kiniksa Pharmaceuticals International, plc
KNSAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeKiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company carries a $4.92B market cap, placing it firmly in the mid-cap category. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Market Cap
$4.92B
Beta
0.07
P/E (TTM)
67.32
P/E (Fwd)
37.56
EPS (TTM)
$0.95
EPS (Fwd)
$1.70
ROE
13.7%
ROA
8.2%
Cash
$468.1M
Total Debt
$9.0M
Free CF
$117.6M
52W Change
120.4%
Annual Financials
Cash vs Debt
With $468.1M in cash and $9.0M in debt, KNSA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $117.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 13.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $220.2M (2022) to $677.6M (2025), reflecting a 208% increase over the period.
KNSA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, KNSA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kiniksa Pharmaceuticals International, plc and its sector.